

1

2 **An optimized reference tissue method for quantification of tau protein depositions**  
3 **in diverse neurodegenerative disorders by PET with <sup>18</sup>F-PM-PBB3 (<sup>18</sup>F-APN-1607)**

4

5 **AUTHORS/AFFILIATIONS:**

6 Kenji Tagai<sup>1,2,5\*</sup>, Yoko Ikoma<sup>1,5</sup>, Hironobu Endo<sup>1</sup>, Oiendriila Bhowmik Debnath<sup>1</sup>, Chie  
7 Seki<sup>1</sup>, Kiwamu Matsuoka<sup>1</sup>, Hideki Matsumoto<sup>1</sup>, Masaki Oya<sup>1</sup>, Kosei Hirata<sup>1</sup>, Hitoshi  
8 Shinotoh<sup>1</sup>, Keisuke Takahata<sup>1,3</sup>, Shin Kurose<sup>1,3</sup>, Yasunori Sano<sup>1,3</sup>, Maiko Ono<sup>1</sup>, Hitoshi  
9 Shimada<sup>1,4</sup>, Kazunori Kawamura<sup>1</sup>, Ming-Rong Zhang<sup>1</sup>, Yuhei Takado<sup>1\*</sup>, Makoto Higuchi<sup>1</sup>

10

11 <sup>1</sup> Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate,  
12 National Institutes for Quantum and Radiological Science and Technology, Chiba 263-  
13 8555, Japan

14 <sup>2</sup> Department of Psychiatry, The Jikei University of Medicine, Tokyo 105-8461, Japan

15 <sup>3</sup> Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan

16 <sup>4</sup> Department of Functional Neurology & Neurosurgery, Center for Integrated Human  
17 Brain Science, Brain Research Institute, Niigata University, Niigata 951-8585, Japan

18 <sup>5</sup> These authors contributed equally

19 \* Correspondence: [tagai.kenji@qst.go.jp](mailto:tagai.kenji@qst.go.jp), [takado.yuhei@qst.go.jp](mailto:takado.yuhei@qst.go.jp)

20

21

22

23

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **ABSTRACT**

2 Positron emission tomography (PET) with  $^{18}\text{F}$ -PM-PBB3 ( $^{18}\text{F}$ -APN-1607) enables high-  
3 contrast detection of tau depositions in various neurodegenerative dementias, including  
4 Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). A simplified  
5 method for quantifying the radioligand binding in target regions is to employ the  
6 cerebellum as a reference (CB-ref) on the assumption that the cerebellum has minimal  
7 tau pathologies. This procedure could be valid in AD, while FTLD disorders exemplified  
8 by progressive supranuclear palsy (PSP) are characterized by occasional tau  
9 accumulations in the cerebellum, hampering the application of CB-ref. The present study  
10 aimed to establish an optimal method for defining reference tissues on  $^{18}\text{F}$ -PM-PBB3-  
11 PET images of the AD and non-AD tauopathy brains. We developed a new algorithm to  
12 extract reference voxels with a low likelihood of containing tau deposits from gray matter  
13 (GM-ref) or white matter (WM-ref) by a bimodal fit to an individual, voxel-wise  
14 histogram of the radioligand retentions and applied it to  $^{18}\text{F}$ -PM-PBB3-PET data obtained  
15 from age-matched 40 healthy controls (HCs) and 23 AD, 40 PSP, and five other tau-  
16 positive FTLD patients. PET images acquired at 90-110 min after injection were averaged  
17 and co-registered to corresponding magnetic resonance imaging space. Subsequently, we  
18 generated standardized uptake value ratio (SUVR) images estimated by CB-ref, GM-ref  
19 and WM-ref respectively, and then compared the diagnostic performances. GM-ref and  
20 WM-ref covered a broad area in HCs and free of voxels located in regions known to bear  
21 high tau burdens in AD and PSP patients. GM-ref allowed the most robust separation of  
22 AD and PSP patients from HCs according to the area under the curves in receiver  
23 operating characteristic curve analyses. GM-ref also provided SUVR images with higher  
24 contrast than CB-ref in FTLD patients with suspected and confirmed corticobasal

1 degeneration. The methodology for determining reference tissues as optimized here  
2 reinforces the accuracy of <sup>18</sup>F-PM-PBB3-PET measurements of tau burdens in a wide  
3 range of neurodegenerative illnesses.

4

5 *KEY WORDS:* tau PET, reference tissues, Alzheimer's disease, progressive  
6 supranuclear palsy, frontotemporal lobar degeneration

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

## 1 **1. Introduction**

2 Depositions of tau fibrils in the brain are the hallmarks of Alzheimer's disease (AD) and  
3 a significant subset of frontotemporal lobar degeneration (FTLD), including progressive  
4 supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick's disease (PiD).  
5 The structures of tau in these and diverse other tauopathies are distinct (1, 2) and  
6 determine the subcellular, cellular, and regional distribution of tau aggregates in close  
7 relationships with clinical phenotypes (3, 4).

8 The recent development of radioligands for positron emission tomography (PET) has  
9 enabled *in vivo* visualization of tau fibril depositions (5, 6). To quantify tau accumulations  
10 in the AD brains, a ratio of the radioactivity uptake between target and reference tissue  
11 defined as standardized uptake value ratio (SUVR) or distribution volume ratio is often  
12 employed as a simplified index for the specific probe binding to tau aggregates under the  
13 assumption that the reference region is devoid of tau lesions harboring binding  
14 components. Similarly, time-radioactivity curves in the target and reference regions are  
15 comparatively utilized for the estimation of non-displaceable binding potential (BP<sub>ND</sub>) of  
16 the radiotracer according to pharmacokinetic models. The reference tissue is primarily  
17 defined on the cerebellar gray matter (CB-ref) for PET measurements of AD-type tau  
18 pathologies since this anatomical structure is supposed to contain minimal tau fibrils in  
19 AD (7-10).

20 While most PET probes for tau deposits are incapable of sensitive detection of FTLD-  
21 type tau assemblies formed by a subgroup of tau isoforms, we developed a PET ligand,  
22 <sup>11</sup>C-PBB3, for visualizing AD and non-AD tau pathologies, including PSP-, CBD-, and  
23 PiD-type tau inclusions (11). <sup>11</sup>C-PBB3 did not yield abundant radiosignals in the brain  
24 due to its high propensity to metabolic conversions and consequent inefficiency of its

1 transfer to the brain, but a fluorinated analog of  $^{11}\text{C}$ -PBB3,  $^{18}\text{F}$ -PM-PBB3 (also known as  
2  $^{18}\text{F}$ -APN-1607), displayed improved biostability and allowed detection of a wide range  
3 of tau lesions with high contrast (12). The use of CB-ref might lead to underestimation of  
4 the radiotracer binding in target tissues, particularly in patients with PSP and CBD, as tau  
5 pathologies could exist in the cerebellum of these cases (13, 14). To circumvent this  
6 technical issue, we extracted reference voxels with a low likelihood of tau depositions  
7 from gray matter in parametric images based on whether the voxel-wise  $\text{BP}_{\text{ND}}$  was within  
8 a range assigned using a histogram in healthy controls (13). This method was applied to  
9 determining  $\text{BP}_{\text{ND}}$  of  $^{11}\text{C}$ -PBB3 in subjects with AD (13), PSP (14), and several other  
10 non-AD tauopathies (15, 16). More recently, other research groups constituted a  
11 procedure to extract reference voxels from white matter based on whether the voxel-wise  
12 radiotracer retention was included in a range assigned using an individual histogram (17,  
13 18). This methodology was then implemented in the estimation of  $^{18}\text{F}$ -PM-PBB3  
14 retention in AD cases (18), and the employment of individual histograms allowed handy  
15 quantitative assays without generating an average histogram in control subjects. However,  
16 it remains unclear whether reference voxels should be collected from gray or white  
17 matter, and how the range of the probe retention in the histogram is selected for the  
18 reference extraction also needs to be determined.

19 The present study aims to establish an optimal method to define reference voxels for the  
20 quantification of  $^{18}\text{F}$ -PM-PBB3 binding in diverse tauopathies. We constructed a new  
21 workflow to assign the range of the probe uptake for picking up adequate voxels with  
22 sufficient robustness in consideration of diverse histogram profiles. Then, the accuracy of  
23 diagnostic discriminations and contrasts for tau pathologies were compared among CB-  
24 ref and pools of reference voxels extracted from gray matter (GM-ref) and white matter

1 (WM-ref).

2

## 3 **2. Methods**

4

### 5 *2.1. Participants*

6 We analyzed age-matched datasets of 40 healthy controls (HCs), 23 patients with AD,  
7 40 patients with PSP, and five patients with other FTLD syndromes. These datasets were  
8 acquired from clinical studies registered in UMIN Clinical Trials Registry (UMIN-CTR;  
9 IDs 000030248, 000034546, 000033808, and 000030319). They were approved by the  
10 Radiation Drug Safety Committee and National Institutes for Quantum Science and  
11 Technology Certified Review Board of Japan. Written informed consent was obtained  
12 from all subjects and/or from close family members when subjects were cognitively  
13 impaired.

14 All patients were clinically diagnosed according to the established criteria as we  
15 previously reported (19-24). Depositions of amyloid-beta ( $A\beta$ ) were assessed by a visual  
16 inspection of  $^{11}C$ -PiB-PET images (12). All AD patients were indicated by PET to have  
17  $A\beta$  plaques and denoted as  $A\beta$  (+), and five  $A\beta$  (+) MCI patients were added to the AD  
18 group. The PSP group consisted of 33 patients with PSP Richardson syndrome (PSP-  
19 Richardson) with typical manifestations and seven patients with other clinical phenotypes  
20 (PSP-other). HCs were without a history of neurological and psychiatric disorders, and  
21 they were age-matched with the AD and PSP groups (Table 1). Patients with other FTLDs,  
22 including corticobasal degeneration syndrome (CBS), progressive non-fluent aphasia  
23 (PNFA), and behavioral variant of frontotemporal dementia (BvFTD), were also  
24 incorporated as in our previous report (12), and two of these cases were

1 neuropathologically diagnosed as having CBD and PiD by biopsy and autopsy,  
2 respectively (25). All HCs, PSP, and other FTLD patients were A $\beta$ (-) according to PET  
3 findings.

4

## 5 *2.2. Image acquisition and data preprocessing*

6 MR images were acquired with a 3-T scanner, MAGNETOM Verio (Siemens  
7 Healthcare). Three-dimensional T1-weighted gradient-echo sequence produced a gapless  
8 series of thin sagittal sections (TE = 1.95 ms, TR = 2300 ms, TI = 900 ms, flip angle =  
9 9°, acquisition matrix = 512×512×176, voxel size = 1 × 0.488 × 0.488 mm). PET assays  
10 were conducted with a Biograph mCT Flow system (Siemens Healthcare), which  
11 provides 109 sections with an axial field of view of 16.2 cm. The intrinsic spatial  
12 resolution was 5.9 mm in-plane and 5.5 mm full-width at half-maximum axially. Images  
13 were reconstructed using a filtered back-projection algorithm with a Hanning filter (4.0  
14 mm full-width at half-maximum). <sup>18</sup>F-PM-PBB3 were injected into the subjects with an  
15 average dose of 186.4 ± 8.2 MBq and a molar activity of 237.4 ± 75.3 GBq/μmol.

16 Data preprocessing was performed using PMOD 3.8 (PMOD Technologies Ltd) and  
17 Statistical Parametric Mapping software (SPM12, Wellcome Department of Cognitive  
18 Neurology). Acquired PET images were corrected for head motions and then rigidly co-  
19 registered to individual T1-weighted MR images. To generate standardized uptake value  
20 ratio (SUVR) images, we averaged PET data acquired at 90 - 110 min after radiotracer  
21 injection. In addition, the individual MR images were segmented, and the probability  
22 maps of gray matter (GM) and white matter (WM) were generated using SPM12 for the  
23 extraction of reference voxels based on histogram analysis.

24

1 *2.3. Histogram-based definition of reference voxels*

2

3 We propose a new method to define reference voxels in GM or WM based on the  
4 frequency histogram of voxel-counts with a homemade script implemented MATLAB  
5 (The Mathworks, Natick, MA, USA). A binary mask image of GM or WM was generated  
6 from the probability maps by selecting voxels with a higher than 90% probability of being  
7 GM or WM. The erosion with morphological operation using 3 x 3 x 3 neighboring voxels  
8 was also conducted on each mask to eliminate influence from the boundary regions.  
9 Subsequently, a voxel-wise frequency histogram of voxel-counts was constructed from  
10 an individual PET image masked for GM or WM.

11 A bimodal Gaussian distribution fit was then applied to the histogram in light of the view  
12 that voxels with and without tau pathologies formed two distinct peaks. The first Gaussian  
13 distribution with the lower-count peak was regarded to contain voxels with no or minimal  
14 tau deposits, and hence voxels with values within the full-width at half-maximum  
15 (FWHM) of this peak were extracted and pooled as a reference region. Tracer retention  
16 in the extracted reference region ( $C_{ref}$ ) was determined by averaging reference voxel  
17 values weighted for the probability of being contained in the first versus second Gaussian  
18 distribution ( $w_i$ ) as follows:

19 
$$C_{ref} = \frac{\sum_{i=1}^N w_i C_i}{\sum_{i=1}^N w_i}$$

20 
$$w_i = g_1(C_i) / (g_1(C_i) + g_2(C_i)),$$

21 where  $C_i$  is the value of the  $i$ 'th voxel,  $g_1$  and  $g_2$  are the first and second Gaussian  
22 distribution functions, respectively, and  $N$  is the number of reference voxels (Figure 1A).

23 If the height of the first peak was less than half of the second peak, we applied



1 monomodal Gaussian distribution to the histogram to circumvent potential lack of the  
2 fitting robustness in the bimodal fit due to an insufficient number of voxels in the first  
3 peak (Figure 1B). The monomodal Gaussian distribution fit was then evaluated by the  
4 Dice coefficient, which is a ratio of the area between the doubled intersection of the  
5 polygonized histogram and fitted Gaussian distribution and the sum of these two polygons.  
6 If the Dice coefficient was smaller than the threshold value determined with HC data in  
7 the current cohort, the bimodal Gaussian distribution fit was considered more appropriate  
8 than the monomodal fit (Figure 1C). The threshold was set at 0.936, which is the mean -  
9 2 standard deviation (SD) value of cases in which monomodal fitting was applied in HCs.  
10 In the use of the monomodal fit,  $C_{ref}$  was determined by averaging counts in all voxels  
11 within the FWHM (Figure 1B). Finally, all voxel-counts were normalized by  $C_{ref}$  in GM-  
12 ref or WM-ref as well as retention in CB-ref (cerebellar cortex) labeled with Freesurfer  
13 6.0 from the Desikan–Killiany–Tourville atlas as a conventional method (25), to produce  
14 SUVR images, respectively.

15

#### 16 *2.4. Target regions*

17

18 The target region was placed at an area with abundant tracer binding in AD and PSP  
19 patients, according to our previous studies (12). We defined volumes of interest (VOIs)  
20 in the neocortex involved in AD tau pathologies at the Braak stages V and VI (BraakV/VI)  
21 and in the subthalamic nucleus (STN) burdened with PSP-type tau deposits. The Braak  
22 V/VI VOI was labeled using FreeSurfer 6.0 as described elsewhere. The STN VOI was  
23 defined with a template atlas (Talairach Daemon atlas from the Wake Forest University  
24 PickAtlas version 3.0.5) in the MNI (Montreal Neurologic Institute) space, and spatial

1 normalization was conducted according to the Diffeomorphic Anatomical Registration  
2 Through Exponentiated Lie Algebra (DARTEL) algorithm. For other FTLDs, VOIs were  
3 also generated with FreeSurfer 6.0 in areas enriched with tau lesions characteristic of each  
4 disease, such as the precentral cortex in CBS and PNFA and the orbitofrontal cortex in  
5 BvFTD.

6

### 7 *2.5. Statistical analyses*

8 Statistical examinations were performed using GraphPad Prism 9.0. We adapted Fisher's  
9 exact test (sex) and Kruskal-Wallis test (other parameters) for comparisons between HCs,  
10 AD, and PSP groups ( $P < 0.05$ , corrected for Dunn's multiple comparisons). The  
11 performance of the diagnosis based on SUVR values in the target VOIs against CB-ref,  
12 GM-ref, and WM-ref was evaluated using Mann-Whitney U test and area under the curve  
13 (AUC) values in Receiver Operating Characteristic (ROC) curves. Subsequently, linear  
14 regression analysis was conducted to assess correlations between SUVRs estimated with  
15 these three reference tissues.

16

## 17 **3. Results**

18

### 19 *3.1. Evaluations of reference tissues*

20

21 Table 1 shows the demography of the subjects and volumes of defined CB-ref, GM-ref,  
22 and WM-ref. The bimodal Gaussian distribution fit to the histogram was judged as  
23 adequate in most cases, while the monomodal fit was chosen in GM histograms of six  
24 HCs and five PSP, and WM histograms of one HC and one AD case. Figure 2

1 demonstrates representative images of GM-ref and WM-ref. As a result of Gaussian  
2 fitting, voxels in GM-ref showed a tendency to pick up from the entire cortex in HCs, the  
3 cerebellum in AD, and regions excluding the cerebellum in PSP cases. Meanwhile, voxels  
4 in WM-ref were extracted from the entire WM in HCs and AD and regions excluding a  
5 WM portion of the basal ganglia in PSP.

6

### 7 *3.2. Diagnostic performance of quantifications with CB-ref, GM-ref, and WM-ref*

8

9 Figure 3 illustrates comparisons of SUVRs in the target VOIs among the AD, PSP, and  
10 HC groups and ROC curve analyses for the discrimination of AD or PSP patients from  
11 HCs. SUVRs determined with all three reference tissues exhibited significant differences  
12 between the patient and HC groups ( $p < 0.05$ , Figure 3A, B), whereas the SD of these  
13 values estimated with WM-ref was higher than those estimated with CB-ref and GM-ref  
14 in HCs (Supplemental Table 1).

15 In ROC curve analyses, the use of CB-ref and GM-ref yielded high AUC values (=   
16 0.998) relative to WM-ref (= 0.985) in the separation between AD patients and HCs  
17 (Figure 3C). GM-ref also produced a higher AUC value (= 0.930) than WM-ref (= 0.923)  
18 and CB-ref (= 0.918) in the discrimination between PSP patients and HCs (Figure 3C).

19

### 20 *3.3. Comparisons of imaging data yielded by CB-ref and GM-ref*

21

22 We then compared parametric SUVR images generated with CB-ref and GM-ref as these  
23 reference tissues enabled better differentiation between the patients and HCs than WM-  
24 ref. The analyses with CB-ref and GM-ref similarly captured spreading of the tracer

1 retention from the medial and inferior temporal regions to the other neocortical areas  
2 along with cognitive declines in the continuum from MCI to AD (Figure 4A). Moreover,  
3 SUVRs in the target VOIs estimated with GM-ref and CB-ref were in good agreement  
4 with each other in MCI and AD cases (Figure 4B). By contrast, the quantification using  
5 GM-ref detected tau depositions in PSP patients with higher SUVR than the analysis with  
6 CB-ref (Figure 5A). Notably, tau accumulations primarily in the midbrain and left  
7 neocortical areas were undetectable with CB-ref but were clearly visualized with GM-ref  
8 in a PSP patient with aphasia (PSP-SL) (Figure 5A). GM-ref yielded higher SUVR values  
9 in the target VOIs than CB-ref in these PSP cases, indicating high contrast for tau  
10 aggregates provided by GM-ref (Figure 5B).

11 We also assessed individual SUVR images of patients with various clinical and/or  
12 neuropathological phenotypes of non-PSP FTLDs (Figure 6). In a case with  
13 neuropathologically confirmed CBD, the assay with GM-ref captured tau depositions in  
14 the motor cortex and subcortical areas more sensitively than the use of CB-ref. Besides,  
15 GM-ref allowed imaging of tau pathologies with topologies characteristic of PSP and  
16 CBD in Non-AD CBS and PNFA patients with higher contrast than CB-ref. Finally,  
17 SUVR images generated with CB-ref and GM-ref displayed high similarity in BvFTD  
18 patients with suspected or confirmed PiD neuropathology, presumably due to the lack of  
19 tau aggregates in the cerebellum.

20

#### 21 **4. Discussion**

22 In the present work, we have optimized the determination of reference tissue for the  
23 sensitive and precise PET detection of tau pathologies in various neurodegenerative  
24 dementias. This methodology reinforces the advantage of  $^{18}\text{F}$ -PM-PBB3 as an imaging

1 agent for AD and non-AD tau depositions. In addition to the conventional CB-ref  
2 placement, Gaussian fits to individual histograms of  $^{18}\text{F}$ -PM-PBB3 retentions in GM and  
3 WM segments provided a range of radioligand uptakes for the extraction of voxels with  
4 a low likelihood of possessing tau deposits. Notably, GM-ref performed as accurately as  
5 CB-ref and better than WM-ref in the discrimination between AD-spectrum cases and  
6 HCs and enabled more robust differentiation of PSP patients from HCs than did CB-ref  
7 and WM-ref. Accordingly, our findings rationalize the utilization of GM-ref for capturing  
8 and quantifying different types of tau accumulations in any of the brain regions, including  
9 the cerebellum.

10 The application of histograms enabled us to exclude regions that were likely to contain  
11 specific binding and to extract optimized reference regions regardless of the type of  
12 diseases (13, 17). A vital issue in the histogram-based definition of reference voxels is the  
13 choice of an adequate mathematical model to describe the observed curves, as  
14 exemplified by monomodal and bimodal Gaussian fits. In the employment of our  
15 precedent tau PET probe,  $^{11}\text{C}$ -PBB3, a relatively low dynamic range for the detection of  
16 specific binding components impeded the application of a bimodal fit to the acquired  
17 image data (11, 13). By contrast, high contrasts for tau deposits produced by  $^{18}\text{F}$ -PM-  
18 PBB3 have allowed clear separation between two histogram clusters representing voxels  
19 with and without noticeable tau pathologies and voxels lacking PET-visible tau fibrils  
20 constitute the first, larger peak (Fig. 1A). Meanwhile, the two peaks can be barely  
21 discriminated in histograms of HCs burdened with few tau aggregates and PSP cases  
22 harboring low-grade tau depositions, justifying the use of a monomodal fit in these  
23 subjects (Fig. 1B). Moreover, the first peak may be small but distinguishable from the  
24 second peak in patients with advanced AD, and GM-ref extracted by the bimodal fitting

1 resembled CB-ref (Fig. 1C).

2 An additional advantage of the current procedure over the previous method (13) is the  
3 assignment of a radioligand uptake range for the selection of reference voxels in each  
4 individual without introducing average cutoff values determined in the HC group. The  
5 group-wise cutoff could vary in a manner dependent on PET scanners and image  
6 reconstruction algorithms, precluding the unification of tau measurements among  
7 different PET facilities. The circumvention of this drawback in the present workflow will  
8 therefore facilitate multicenter tau PET assessments of elderly subjects on a large scale.

9 In this study, GM-ref yielded higher AUC values in the ROC analysis than WM-ref  
10 across the diseases, which was primarily attributed to the variability in the quantification  
11 of SUVRs with WM-ref in HCs. WM-ref had been reported to be valid in several amyloid  
12 and tau PET studies (17, 26, 27) as its large size could be advantageous for reducing the  
13 statistical variability relative to CB-ref. In the meantime, non-specific retentions of these  
14 radioprobes in WM areas have been observed to vary among HCs partially in relation to  
15 aging (28, 29). It is also noteworthy that even slight alterations of off-target tracer binding  
16 may lead to large variabilities of SUVRs in the use of WM-ref if the background (free)  
17 tracer retention in WM is very low. Although factors affecting the non-displaceable  
18 uptake of  $^{18}\text{F}$ -PM-PBB3 in WM are yet to be identified, we consider GM-ref to be  
19 preferable to WM-ref for the quantification of tau deposits with this radioligand.

20 GM-ref also exhibited better diagnostic performance than CB-ref in patients with FTLN  
21 disorders, particularly in those with putative and confirmed PSP and CBD pathologies.  
22 Indeed, PSP tau pathologies could involve the cerebellar dentate nucleus and adjacent  
23 WM from a relatively early stage (30, 31). Similarly, tau lesions can be found in these  
24 areas of atypical or advanced CBD cases (32-34). Furthermore, tau inclusions in

1 cerebellar GM Purkinje cells have also been detected in both PSP and CBD patients (35,  
2 36). Thus, the localization of these pathological tau aggregates could undermine the  
3 validity of CB-ref for the PET assessment of FTLD disorders. The histogram-based  
4 reference definition proposed here can exclude voxels with potential tau pathologies  
5 throughout the entire GM or WM, including the cerebellar regions, in an unbiased fashion.  
6 In fact, GM-ref was composed of extensive neocortical areas rather than the cerebellar  
7 sectors in consecutive PSP and CBD cases, along with CBS and PNFA patients suspected  
8 of having PSP or CBD pathologies, and low-grade tau accumulations in neocortical  
9 structures of these subjects could be captured by using GM-ref but not CB-ref. By contrast,  
10 tau depositions in PiD patients were nearly equally detectable by applying GM-ref and  
11 CB-ref, in agreement with the lack of intense cerebellar tau lesions in this disorder.

12 As mentioned above, GM-ref and CB-ref showed comparable diagnostic performance  
13 in discriminating AD cases from HCs. We also postulate that GM-ref can utilize a larger  
14 volume of brain areas than CB-ref in the assays of patients with prodromal and early AD,  
15 contributing to a gain of the quantification stability. This potential benefit would help  
16 sensitive detection of tau accumulations with low abundances in incipient AD.

17 In conclusion, the newly developed workflow for the determination of reference tissue  
18 fortifies the utility of  $^{18}\text{F}$ -PM-PBB3 for investigating a broad spectrum of  
19 neurodegenerative tauopathies with high contrast. The tau PET technology in conjunction  
20 with this quantitative procedure will also permit longitudinal measurements of tau  
21 aggregates with minimal influences of temporal changes in specific and non-displaceable  
22 binding components at a certain location, which is advantageous in the evaluation of  
23 emerging anti-tau therapeutics for AD and FTLD disorders.

24

## 1 **Funding**

2 This study was supported in part by AMED under Grant Number JP18dm0207018,  
3 JP19dm0207072, JP18dk0207026, JP19dk0207049, and by MEXT KAKENHI Grant  
4 Number JP16H05324, JP18K07543, by JST CREST Grant Number JPMJCR1652 and by  
5 Biogen Idec Inc. and APRINOIA Therapeutics.

6

## 7 **Data accessibility**

8 Requests for data that support the findings of this study should be directed to  
9 Correspondence, Kenji Tagai (tagai.kenji@qst.go.jp) and Yuhei Takado  
10 (takado.yuhei@qst.go.jp), and will be available upon reasonable request.

11

## 12 **Declaration of Competing Interest**

13 Hitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on compounds  
14 related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).

15

## 16 **Credit authorship contribution statement**

17 **Kenji Tagai, Yoko Ikoma:** Conceptualization, Methodology, Formal analysis, Writing -  
18 original draft. **Hironobu Endo, Oriendrila Debnath, Chie Seki, Maiko Ono:**  
19 Conceptualization, Methodology. **Kiwamu Matsuoka, Keisuke Takahata, Hitoshi**  
20 **Shinotoh, Hideki Matsumoto, Masaki Oya, Kosei Hirata, Shin Kurose, Yasunori**  
21 **Sano, Hitoshi Shimada:** Collection of clinical data. **Kazunori Kawamura, Ming-Rong**  
22 **Zhang:** Radioligand synthesis. **Yuhei Takado, Makoto Higuchi:** Conceptualization,  
23 Writing - review & editing, Funding acquisition, Supervision

24



## 1 **Acknowledgements**

2 The authors thank all patients and their caregivers for participation in this study, as well  
3 as clinical research coordinators, PET and MRI operators, radiochemists, and research  
4 ethics advisers at QST for their assistance with the current projects. We thank APRINOIA  
5 Therapeutics for kindly sharing a precursor of  $^{18}\text{F}$ -PM-PBB3. The authors acknowledge  
6 support with the recruitment of patients by Shunichiro Shinagawa at the Department of  
7 Psychiatry, Jikei University School of Medicine; Shigeki Hirano at the Department of  
8 Neurology, Chiba University; Taku Hatano, Yumiko Motoi, and Shinji Saiki at the  
9 Department of Neurology, Juntendo University School of Medicine; Ikuko Aiba at the  
10 Department of Neurology, National Hospital Organization Higashinagoya National  
11 Hospital; Yasushi Shiio and Tomonari Seki at the Department of Neurology, Tokyo  
12 Teishin Hospital; Hisaomi Suzuki at the National Hospital Organization Shimofusa  
13 Psychiatric Medical Center.

## 14 15 **Supplementary materials**

16 Supplementary material associated with this article can be found in the online version.

## 17 18 **References:**


- 19  
20 1. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms,  
21 phosphorylation and role in neurodegenerative disorders. *Brain Res Brain Res Rev.* 2000;33(1):95–  
22 130.
- 23 2. Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, et al. Structure-based classification  
24 of tauopathies. *Nature.* 2021;598(7880):359–63.
- 25 3. Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron  
26 microscopic demonstration of tau filaments in tauopathies. *Neuropathology.* 2006;26(5):475–83.
- 27 4. Delacourte A. Tauopathies: recent insights into old diseases. *Folia Neuropathol.*

- 1 2005;43(4):244–57.
- 2 5. Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta  
3 proteinopathies in Alzheimer disease and other conditions. *Nat Rev Neurol*. 2018;14(4):225–36.
- 4 6. Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET  
5 imaging in neurodegenerative tauopathies—still a challenge. *Mol Psychiatry*. 2019;24(8):1112–34.
- 6 7. Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, et al. Kinetic Modeling  
7 of the Tau PET Tracer  $(^{18}\text{F})\text{-AV-1451}$  in Human Healthy Volunteers and Alzheimer Disease Subjects.  
8 *J Nucl Med*. 2017;58(7):1124–31.
- 9 8. Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo  
10 quantification of neurofibrillary tangles with  $(^{18}\text{F})\text{MK-6240}$ . *Alzheimers Res Ther*. 2018;10(1):74.
- 11 9. Kuwabara H, Comley RA, Borroni E, Honer M, Kitmiller K, Roberts J, et al. Evaluation of  
12  $(^{18}\text{F})\text{-RO-948}$  PET for Quantitative Assessment of Tau Accumulation in the Human Brain. *J Nucl Med*.  
13 2018;59(12):1877–84.
- 14 10. Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with  
15  $(^{18}\text{F})\text{-PI-2620}$  in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study.  
16 *J Nucl Med*. 2020;61(6):911–9.
- 17 11. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology  
18 in a tauopathy mouse model and in Alzheimer patients compared to normal controls. *Neuron*.  
19 2013;79(6):1094–108.
- 20 12. Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-Contrast In Vivo  
21 Imaging of Tau Pathologies in Alzheimers and Non-Alzheimers Disease Tauopathies. *Neuron*.  
22 2021;109(1):42–58 e8.
- 23 13. Kimura Y, Endo H, Ichise M, Shimada H, Seki C, Ikoma Y, et al. A new method to quantify tau  
24 pathologies with  $(^{11}\text{C})\text{-PBB3}$  PET using reference tissue voxels extracted from brain cortical gray  
25 matter. *EJNMMI Res*. 2016;6(1):24.
- 26 14. Endo H, Shimada H, Sahara N, Ono M, Koga S, Kitamura S, et al. In vivo binding of a tau  
27 imaging probe,  $(^{11}\text{C})\text{PBB3}$ , in patients with progressive supranuclear palsy. *Mov Disord*.  
28 2019;34(5):744–54.
- 29 15. Shinotoh H, Shimada H, Kokubo Y, Tagai K, Niwa F, Kitamura S, et al. Tau imaging detects  
30 distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula. *Neurology*.  
31 2019;92(2):e136–e47.
- 32 16. Takahata K, Kimura Y, Sahara N, Koga S, Shimada H, Ichise M, et al. PET-detectable tau  
33 pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain  
34 injury. *Brain*. 2019;142(10):3265–79.
- 35 17. Southekal S, Devous MD, Sr., Kennedy I, Navitsky M, Lu M, Joshi AD, et al. Flortaucipir F 18  
36 Quantitation Using Parametric Estimation of Reference Signal Intensity. *J Nucl Med*.

- 1 2018;59(6):944–51.
- 2 18. Zhang H, Wang M, Lu J, Bao W, Li L, Jiang J, et al. Parametric Estimation of Reference Signal  
3 Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [ $^{18}\text{F}$ ]-APN-1607 Study.  
4 *Front Neurosci.* 2021;15:598234.
- 5 19. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive  
6 impairment: clinical characterization and outcome. *Arch Neurol.* 1999;56(3):303–8.
- 7 20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of  
8 Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of  
9 Health and Human Services Task Force on Alzheimers Disease. *Neurology.* 1984;34(7):939–44.
- 10 21. Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical  
11 diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord.*  
12 2017;32(6):853–64.
- 13 22. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis  
14 of corticobasal degeneration. *Neurology.* 2013;80(5):496–503.
- 15 23. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of  
16 revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain.*  
17 2011;134(Pt 9):2456–77.
- 18 24. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al.  
19 Classification of primary progressive aphasia and its variants. *Neurology.* 2011;76(11):1006–14.
- 20 25. Klein A, Tourville J. 101 labeled brain images and a consistent human cortical labeling  
21 protocol. *Front Neurosci.* 2012;6:171.
- 22 26. Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for  
23 characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments  
24 with a cerebral white matter reference region. *J Nucl Med.* 2015;56(4):560–6.
- 25 27. Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of  
26 longitudinal beta-amyloid change with  $^{18}\text{F}$ -florbetapir PET and standardized uptake value ratios. *J*  
27 *Nucl Med.* 2015;56(4):567–74.
- 28 28. Baker SL, Harrison TM, Maass A, La Joie R, Jagust WJ. Effect of Off-Target Binding on  $^{18}\text{F}$ -  
29 Flortaucipir Variability in Healthy Controls Across the Life Span. *J Nucl Med.* 2019;60(10):1444–51.
- 30 29. Moscoso A, Grothe MJ, Scholl M, Alzheimers Disease Neuroimaging I. Reduced  
31 [ $^{18}\text{F}$ ]flortaucipir retention in white matter hyperintensities compared to normal-appearing white  
32 matter. *Eur J Nucl Med Mol Imaging.* 2021;48(7):2283–94.
- 33 30. Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, et al. Distribution patterns  
34 of tau pathology in progressive supranuclear palsy. *Acta Neuropathol.* 2020;140(2):99–119.
- 35 31. Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden  
36 and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardsons

- 1 syndrome. *Brain*. 2007;130(Pt 6):1566–76.
- 2 32. Kouri N, Murray ME, Hassan A, Rademakers R, Uitti RJ, Boeve BF, et al. Neuropathological  
3 features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome.  
4 *Brain*. 2011;134(Pt 11):3264–75.
- 5 33. Ling H, Kovacs GG, Vonsattel JP, Davey K, Mok KY, Hardy J, et al. Astroglial pathology predominates  
6 the earliest stage of corticobasal degeneration pathology. *Brain*. 2016;139(Pt 12):3237–52.
- 7 34. Shiozawa M, Fukutani Y, Sasaki K, Isaki K, Hamano T, Hirayama M, et al. Corticobasal  
8 degeneration: an autopsy case clinically diagnosed as progressive supranuclear palsy. *Clin*  
9 *Neuropathol*. 2000;19(4):192–9.
- 10 35. Piao YS, Hayashi S, Wakabayashi K, Kakita A, Aida I, Yamada M, et al. Cerebellar cortical tau  
11 pathology in progressive supranuclear palsy and corticobasal degeneration. *Acta Neuropathol*.  
12 2002;103(5):469–74.
- 13 36. Koga S, Josephs KA, Ogaki K, Labbe C, Uitti RJ, Graff-Radford N, et al. Cerebellar ataxia in  
14 progressive supranuclear palsy: An autopsy study of PSP-C. *Mov Disord*. 2016;31(5):653–62.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27




1

2 **Figure 1: Flowcharts of extracting reference tissues by developed algorithm on  $^{18}\text{F}$ -**  
 3 **PM-PBB3 PET images.**

4 The yellow-labeled regions show extracted references based on bimodal/monomodal  
 5 Gaussian fitting, respectively.

6 (A) A histogram obtained from a PSP-Richardson case, and the reference was extracted  
 7 from the 1st Gaussian distribution based on bimodal fitting. (B) shows histograms  
 8 obtained from a PSP-PGF case. The amplitude of the 1st peak was less than half of the  
 9 2nd peak on bimodal fitting (left), and the Dice coefficient was higher than the threshold  
 10 value ( $>0.939$ ) on monomodal fitting (right). Hence, the reference was set based on  
 11 monomodal fitting. (C) shows histograms obtained from an AD case. The amplitude of  
 12 the 1st peak was less than half of the 2nd peak on bimodal fitting (left), whereas the Dice  
 13 coefficient was lower than the threshold value ( $<0.939$ ) on monomodal fitting (right).  
 14 Ultimately, the reference was set based on bimodal fitting.

1




2

3 **Figure 2: Comparisons of characteristics of GM-ref and WM-ref generated using**  
4 **histograms.**

5 References generated by the histograms in representative cases of HCs and patients with  
6 AD and PSP. All PET images were co-registered T1-weighted MR images; red labeled  
7 regions demonstrate generated GM-ref (upper row); yellow labeled regions show WM-  
8 ref (lower row).

9

10



1

2 **Figure 3: Comparison of diagnostic performances for discriminating patients from**  
 3 **HCs between each reference.**

4 (A, B) Scatter plots show SUVR values of Braak V/VI (A) and STN (B) in the case of  
 5 quantified by each reference. The color of each dot indicates the clinical profile: Black  
 6 circles; (HC), white squares; (MCI), black squares; (AD), blue circles; (PSP-Richardson)  
 7 and red circles; (PSP-other). Asterisks represent  $P < 0.05$  by Mann-Whitney U test.

8 (C) ROC curves estimated from each reference are shown for the following groups:

1 HCs vs MCI/AD (left) and PSP (right). Each color shows the type of references: black  
2 (CB-ref), blue (GM-ref), and red (WM-ref).

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20



21

22

23

24






1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

**Figure 4: Direct comparison of SUVRs quantified by CB-ref and GM-ref in HCs and AD patients.**

(A) SUVR parametric images quantified by CB-ref in the upper row and by GM-ref in the lower row are shown. Tau lesions are visualized with similar contrast to CB-ref from MCI to AD.

(B) The Scatterplot demonstrates a linear regression analysis. Black circles: (HC), white squares: (MCI), black squares: (AD). SUVR values are estimated from BraakV/VI VOI.




1  
2 **Figure 5: Direct comparison of SUVRs quantified by CB-ref and GM-ref in HCs and**  
3 **PSP patients.**

4 (A) SUVR parametric images quantified by CB-ref in the upper row and by GM-ref in  
5 the lower row are shown. Tracer retention was increased and visualized in GM-ref  
6 compared to CB-ref in areas with well-known PSP pathology such as basal ganglia  
7 (white arrowheads) and motor cortex (yellow arrowheads). The asterisk image was  
8 obtained from a neuropathologically confirmed PSP patient.

9 (B) The Scatterplot demonstrates a linear regression analysis. Blue circles, (PSP-  
10 Richardson); red circles, (PSP with other clinical phenotypes). SUVR values are  
11 estimated from STN VOI.

12



**Figure 6: Direct comparison of SUVRs quantified by CB-ref and GM-ref in other FTLN patients.**

(A) SUVR parametric images quantified by CB-ref in upper row and by GM-ref in lower row are shown. Tracer retention was increased and visualized in GM-ref compared to CB-ref in CBD, Non-AD CBS, PNFA and patients but remained almost the same in BvFTD and PiD patients. Arrowheads indicate each target region: motor (yellow) and orbito (white) frontal cortices. Asterisk images were derived from neuropathologically confirmed patients.

(B) Comparison of SUVR values quantified by CB-ref and GM-ref in each target region. Each target region was set at precentral cortex of CBD (magenta triangle), Non-AD CBS (magenta circle) and PNFA (magenta square) patients, and orbitofrontal cortex of BvFTD (light blue circle) and PiD (light blue triangle).

1 **Table 1: Demographics and characteristics of each reference**

2

	HC	AD	PSP
Demographics			
Number	40	23	40
Age	68.6 (5.7)	66.2 (10.0)	70.4 (6.4)
Gender (male/female)	25/15	11/12	22/18
MMSE	28.3 (1.5)	21.8 (3.7) <sup>*†</sup>	24.8 (4.6) <sup>*</sup>
PSPRS	N/A	N/A	38.1 (18.2)
Volumes of reference (cm <sup>3</sup> )			
CB-ref	62.8 (7.3)	65.3 (11.1)	60.4 (9.7)
GM-ref	124.6 (31.0)	52.5 (21.6) <sup>*†</sup>	95.8 (36.2) <sup>*</sup>
WM-ref	157.6 (28.1)	144.8 (26.9)	142.8 (29.4) <sup>*</sup>

3

4 HC, healthy control; AD, Alzheimer’s disease; PSP, progressive supranuclear palsy;  
 5 MMSE, mini-mental state examination; PSPRS, progressive supranuclear palsy rating  
 6 scale; CB-ref, cerebellar reference; GM-ref, gray matter reference; WM-ref, white matter  
 7 reference

8 PSP patients consisted of 33 PSP-Richardson and seven PSP with other clinical  
 9 phenotypes: PSP with progressive gait freezing (PSP-PGF), predominant parkinsonism  
 10 (PSP-P), and predominant speech/ language disorder (PSP-SL).

11 Values are listed as mean ± standard deviation.

12 <sup>\*</sup>, HC higher than AD and PSP,  $P < 0.05$

13 <sup>†</sup>, PSP higher than AD,  $P < 0.05$